返回 Agenda
Session 9 Track 3: Field Medical and Engagement with Payers
Session Chair(s)
Iris Tam, PharmD
Senior Vice President and Head, Medical Affairs and HEOR
COEUS, United States
Session speakers will navigate the journey of a product from clinical development through commercialization, highlighting the diverse responsibilities and critical activities of medical field personnel in driving product value and market access. This session will cover strategies and insights from pre-launch through post-launch and throughout the product lifecycle. Ideal for therapeutic medical science liaisons seeking to enhance their understanding of payer interactions or explore career pathways into field medical market access roles, as well as professionals responsible for shaping medical affairs strategies.
Learning Objective : - List and explain two essential tools developed by Medical Affairs to effectively communicate product value to payers
-
Describe critical topics or activities that Medical Affairs field teams should prioritize to support payer engagement during the pre-approval phase of a pipeline product
- Discuss key strategies for field medical teams to successfully engage with payers and support market access during the launch of a new product and throughout its life cycle
Speaker(s)
Field Payer Engagement: During the Pre-Approval Period
Patricia Bourne, PharmD
Cytokinetics, United States
Senior Director, Medical Sciences
Account Prioritization and Engagement Strategy
Lee Ding, PharmD, RPh
BeiGene, United States
Senior Director, Medical Value and Outcomes
Creative Value Story and Evidence Generation
Stuart O’Brochta, PharmD
Gilead, United States
Executive Medical Value and Evidence Liasion, US Medical Affairs